"It puts an end of the first day off" .. a new medicine to prevent migraine

In a recent study, it was revealed that a new drug, which has recently been approved to prevent migraines, can start working immediately, which represents great progress in the field of treating this disease. According to the study published in the “Neuron” Medical Journal of the American Academy of Neuroscience, the use of the drug “atogpant” migraine “prevents the first day”. Current medication to prevent migraines, a long time should adjust the ideal dose of the patient, and it may take weeks or even months to show its effectiveness completely, causing some patients to stop treatment before reaching the desired results. Many patients also suffer from the side effects of current medication, thus developing a drug that works quickly and effectively is a decisive step. ATGUBANT has been approved to prevent extensive migraine among adults in the United States since September 2021, and in the European Union since August 2023. In Europe, this remedy is used to prevent migraines from people suffering for four days or longer. How does the medicine “atogibant” work? ATPIPONT works to impede receptors called CGRP, which reduces the number of migraine days in patients. When migraines occur, the peripheral nerves are secreted in the brain, which acts as a chemical signal that causes blood vessels and increases the inflammation around the nerves in the brain, leading to a sense of pain and migraine. CGRP is related to its receptors on the walls of the blood vessels and nerve cells, leading to the beginning of a series of events causing a migraine attack. ‘Atogibant’ discourages CGRP receptors directly by linking it and preventing this substance from dealing with it, which occurs signals that lead to the expansion of blood vessels and inflammation, and reduce the possibility of migraine attacks. Two major clinical experiences have shown previous previous efficiency to reduce the number of migraine days monthly, and improve the quality of life in patients suffering from soil and chronic migraines over 12 weeks compared to the imaginary agent. Abbvie Medicine has developed this medicine, which was evaluated by the benefits and side effects in two experiments that include 1562 participants who suffered with migraine on a satisfactory date. Studies also included a comparison between groups that took different doses of “Atogibant”, and others who took a false drug over a 3 -month period. On the first day of the new experiment, the data shows a noticeable effectiveness of the drug “Atogibant” to reduce the incidence of migraine attacks. In the first experiment, only 12% of participants who took the medicine over a migraine attack compared to 25% of the group that took a false medicine, while the percentage was 15% compared to 26% in a second experiment, and 51% compared to 61% in a third experience when other factors could be adjusted. Participants who took the medicine were 61% less likely to develop migraine attacks in the first experiment, 47% per second, and 37% in the third. As for the weekly migraine days, the rate dropped by one day a week in the first and second experiments in the group that took the drug, compared to a decrease of less than half a day in the group that took a fake medicine, while the rate fell by 1.5 days a week in the third experiment, compared to one day. The results show a great improvement in the quality of life and the ability to perform daily activities with people who have taken ‘atogibant’. Side effects of the middle “atogbant”. The researchers said that migraine is the second cause of disability worldwide, and the first among young women, as it negatively affects relationships, to increase children, professional life and financial conditions, thus the availability of treatment that works quickly and effectively is a response to an important need for patients. Despite the great effectiveness of preventing migraine, ‘atogibant can cause side effects that need to be taken into account when used. These effects include nausea, constipation, fatigue or drowsiness, reduced appetite and low weight. It is important for patients to follow their cases with treated doctors to judge benefits in exchange for any side effects that can occur, and to ensure the safe use of the drug.